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To the Editor,
Defective elimination of nucleic acids can trigger autoinflammatory and autoimmune processes (1) . Mice lacking the lysosomal endonucleases DNase-II have shown intracellular DNA accumulation leading to severe anemia and embryonic death (2) . Humans carrying homozygous non-synonymous loss-of-function mutations in DNASE2 complete gestation, but are severely affected by congenital anemia and an inflammatory disorder characterised by splenomegaly, glomerulonephritis, liver fibrosis, circulating anti-DNA auto-antibodies, and progressive arthritis (3) .
We describe a patient with a novel hypomorphic homozygous missense mutation in DNASE2 The proband (V-2) is a 14-year-old Somalian girl from endogamous kindred with a history of neonatal anemia (Fig. 1A) . At 6 years of age, patient V-2 was referred for pyrexia; a history of pancytopenia, hepatosplenomegaly, failure to thrive (height and weight below the 0.4 th percentile), chronic diarrhoea and delayed motor skill development. Investigations (summarized in Table S1 ) revealed severe pancytopenia, requiring multiple transfusions of red cells and platelets. Intestinal histology from endoscopic biopsies revealed multiple granuloma-like cells within mucosa-associated lymphoid tissue, compatible with phagocytosed DNA fragments (pseudo-granuloma). Magnetic resonance imaging of the brain revealed bi-parietal deep white matter parenchymal signal abnormalities ( Fig. 1B) . Bone marrow studies identified macrophage infiltration and associated haemophagocytosis (Fig. 1C) . At 9 years of age, the patient experienced severe Epstein Barr virus infection, necessitating treatment with dexamethasone and rituximab. Typical HLH criteria were met (Table S1 ). She responded partially to the HLH-2004 chemotherapy treatment protocol which she had for 7 weeks (4) with cessation of fever, and improvement in diarrhoea, but with ongoing pancytopenia and hepatosplenomegaly. For several years, transfusion-dependent anemia, chronic diarrhoea, and severe growth retardation were observed.
Homozygosity mapping and whole exome sequencing revealed a rare homozygous variant in DNASE2 (c.284A>G; p.Y95C; Table S2 , Fig. S1A ). The affected variant is highly conserved across species (Fig. 1D) . We used structural data of existing DNase-II homodimer complexed with double-stranded DNA crystal structure from Burkholderia thailandensis to model the human DNase-II (5) . Residue Y95 is closely packed with residue T114, which is central to the nuclease catalytic HxK motif (H113 and K115) suggesting that small perturbations at residue 95 may have significant impact on catalytic activity. The two recently published mutations in DNASE2 (p.G116A and p.D121V) (3) will likely disrupt the same catalytic domain (Fig. 1E) .
The p.Y95C variant completely abolishes DNase-II activity in a single radial enzyme diffusion ( Fig. S1B) and confers loss-of-function of the protein rather than absence ( Fig. S1C-D) .
Furthermore, granulocyte lysates from V-2 confirmed a deficiency in degrading DNA ( Fig.   1F ).
Macrophages show highest expression of DNASE2 and are most likely affected in DNase-II deficient patients ( Fig. S2A) . We observed increased lysosomal DNA accumulation in monocyte-derived macrophages from V-2 compared to controls, (Fig. S2B) . Similarly, clearance of exogenous apoptotic or bacterial derived DNA was reduced in V-2 macrophages ( Fig. S2C-2D ). To investigate whether DNase-II deficiency causes a selective DNA degradation defect or broadly affects lysosomal function, we tested antimicrobial activity in V-2 macrophages (Fig. S2E) . Normal antimicrobial activity suggests that the defect in DNASE2 patients is restricted to the inability to clear DNA.
Previous studies emphasized that deficiency in DNASE2 in humans and mice results in the induction of interferon, and non-interferon-mediated inflammation (2, 3, 6, 7) . Elevated levels of TNF, MCP-1, IL-18, IFN-2α, IFN-β, and IFN-γ were detected in sera of V-2 ( Fig. 1G) .
Increased levels of TNF, IL-1β, IP-10 and IL-8 were observed in V-2 fibroblasts ( Fig. S3A) . p.Y95C macrophages showed high levels of TNF and IL18, modestly increased IL-1β, and a clear induction of type I IFNs (Fig. S3B) , which we also confirmed to be present in one of the previously described patients (3) ( Fig. S3B) .
Type I interferons (IFN-α and IFN-β) bind to type I receptors (IFNAR1/2) and induce the activation of JAK1 and TYK2, leading to STAT1 and STAT2 phosphorylation and interferon stimulated gene (ISG) expression (8) . Since the immunotype of V-2 was indicative of a strong ISG signature, we explored JAK inhibition as a therapeutic option. In vitro JAK1/JAK2 blockade with baricitinib reduced ISG expression in fibroblasts from controls, patient V-2, and control macrophages following IFN-α stimulation ( Fig. S4A-B) . In contrast, selective blockade of JAK2 using AG490 did not revert the ISG signature (Fig. S4A) . In healthy macrophages, baricitinib treatment had stronger effects on ISG reduction compared to fibroblasts (Fig. S4B) .
IFN-α-induced IL18 levels were reduced following baricitinib or AG490 treatment ( Fig. S4C ), suggesting a contribution of JAK2 signalling to IL18 production in control macrophages.
Since JAK inhibitors are effective in several interferonopathies (9) , and baricitinib reverted the inflammatory signature in fibroblasts and macrophages in vitro, we treated our otherwise therapy non-responsive patient with baricitinib. We started with 2mg oral dose once daily, increasing weekly by 2 mg to achieve a final target dose of 2 mg, 3 times a day. Baricitinib was well tolerated with no adverse events, and resulted in a rapid and sustained clinical improvement (now for over 6 months). In particular, the improved energy levels reported by the patient and the ability to attend school full-time were relevant patient reported outcomes.
Weight gain improved ( Fig. 2A) , and the patient underwent menarche 4 months after starting baricitinib. Blood parameters ( Fig. 2B) , gastrointestinal symptoms, and faecal calprotectin levels improved ( Fig. 2B) . Baricitinib decreased ISG expression in the peripheral blood and cytokine levels compared to pre-treatment levels ( Fig. 2C-E) . After 6 months of treatment, however, whilst the ISG signature indicated normalisation of SIGLEC1 and ISG15, there was an upward trend of IFIT1, IFI44L, RSDA2, IL-18 and IFI27 despite ongoing therapeutic response. Our data suggest that JAK1/2 inhibition is a rational and effective treatment for DNase-II deficiency.
In conclusion, we describe an additional patient with human DNase-II deficiency who presented with HLH and early-onset intestinal inflammation, expanding the phenotype spectrum of DNase-II deficiency. We characterize the mechanisms underpinning the complex immunophenotype, and show in a single patient that blocking JAK1/JAK2 with baricitinib can be used to curb pathological interferon signaling caused by an inability to clear intracellular DNA. 
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Structural modelling
Structural models and figures were prepared using the ICM software package (Molsoft). A homology model for human DNase II was prepared using the existing structure from
Burkholderia thailandensis (PDB 5unb) as the model template. Double-stranded DNA (PDB 2bna) was positioned manually at the dimer interface to indicate the potential DNA binding surface as previously highlighted (10) . All coordinate files were obtained from the Protein Data Bank (http://www.rcsb.org). 
PBMC isolation and monocyte-derived macrophage cell culture

DNA degradation assay in granulocytes and COS-7 cells
Granulocytes were purified from the precipitate after the blood gradient by removing red blood cells with ACK lysis buffer (Invitrogen). Gel densitometry analysis was done by use of ImageJ program.
Human DNASE2 cDNA sequence was cloned into the expression pcDNA3.1 (+) vector (Invitrogen, San Diego, CA) (11) and used as a wild-type construct. The variant construct corresponding to p.Y95C in DNASE2 was inserted into the wild type template using the KOD-Plus Mutagenesis kit (Toyobo Co., Ltd., Osaka, Japan). Nucleotide sequences of the construct were confirmed by DNA sequence analysis. Purification of each construct used for transfection was performed using the Plasmid Midi kit (Qiagen).
DNase II activity in the transfected COS-7 cells was assayed by the single radial enzyme diffusion method using a LAS-3000 imaging analyzer (Fuji Film, Tokyo, Japan) according to our previous reports (12). The activity of wild-type DNase II was defined as 1.0, and that of the amino acid-substituted DNase II was expressed relative to the wild type. with PBS-PFA 4% solution for 10 minutes at 37 C and then washed. Slides were mounted with a glass coverslip by using vectashield solution (Vector Laboratories). Images were captured using a Nikon eclipse ME600 fluorescence microscope, and analyzed with ImageJ.
Immunofluorescence cell staining
Gentamycin protection assay
Macrophages at day 5 of differentiation were detached with Versene (Gibco) for 5 minutes and counted. 2 x10 4 macrophages were seeded per well in 96 well plates. Then, they were infected with Salmonella typhimurium at MOI 1:10 for 1 hour. Followed 2 hours of treatment with 100 µg/ml of gentamicin (Sigma-Aldrich). Cells were then lysates in 50 µl of Triton 1X. Undiluted and diluted 1:10 and 1:100 cell lysates were plated in LB-agar plates that were incubated O.N.
at 37 o C. Bacterial colonies were manually counted.
Macrophage and fibroblast stimulations
Healthy donor macrophages (1x10 5 
RNA expression analysis in total blood, fibroblasts and macrophages.
Whole blood was collected into PAXgene tubes. We used a PreAnalytix RNA isolation kit for whole blood and the RNeasy Micro Kit (Qiagen) for RNA isolation from macrophages and fibroblasts. The RNA concentration was assessed with a Nanodrop (FLUOstar Omega, Labtech). Total RNA was retrotranscribed to cDNA using the Reverse Transcription kit (Applied Biosystems). We performed quantitative polymerase chain reaction (qPCR) analysis using the iTaq Universal SYBR Green Supermix (172-5121, Bio-Rad) and the TaqMan Gene Expression Assay (FAM) (Applied Biosystems).
The relative abundance of each of 6 'interferon score' target (IFL27, IFIT1, IFI44L, ISG15 and RSAD2) and other pro inflammatory transcripts was normalized to the expression level of HPRT1 or RPLPO assessed using Bio Rad CFX Maestro software.
Cytokine protein analysis using ELISA and multiplex assay
Cytokine levels were measured in the serum of patients and controls, and in supernatants of were assayed for TNF, IL1-ß and IL18 cytokines using ProcartaPlex-Multiplex Immunoassay (Invitrogen). 
Statistical analyses Supplementary
